STAT2h
Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
STAT5d
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Yahoo Finance2h
Toragen reports positive results from trial of TGN-S11 for HPV-related cancer
The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured ...
FierceBiotech6d
BioNTech pays $800M to take control of potential Keytruda killer
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
BioPharma Dive4d
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
FierceBiotech5d
Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Zacks.com on MSN23h
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...